Pancreatic cancer vaccine with positive results
None developed cancer after median follow-up of 16.5 months
- Center1
- Center-right4
4 agency rewrites / co-publications detected
Summary
None developed cancer after median follow-up of 16.5 months. A trial with 20 high-risk people showed that mKRAS-VAX activated immune cells in 18 participants. They also warned that the small sample size and the relatively short follow-up period limit conclusions on clinical efficacy.
Furthermore, The study evaluated mKRAS-VAX, a peptide-based vaccine that targets the six most common mutations of the KRAS gene found in pancreatic cancer.
Cross-referenced from 5 sources.
Factual coreconfirmed by several independent voices
None developed cancer after median follow-up of 16.5 months
reliability low1/5 sourcesA trial with 20 high-risk people showed that mKRAS-VAX activated immune cells in 18 participants.
reliability low1/4 sources
Reported detailssecondary facts, each attributed to its source
They also warned that the small sample size and the relatively short follow-up period limit conclusions on clinical efficacy.
according to Notícias ao Minuto — MundoThe study evaluated mKRAS-VAX, a peptide-based vaccine that targets the six most common mutations of the KRAS gene found in pancreatic cancer.
according to Notícias ao Minuto — Mundo
Disputedincompatible versions — to verify
No factual contradiction detected between sources.
Framing by sidesame fact, different words — loaded terms highlighted
No notable framing divergence.
Blind spotwhat one side keeps silent
A trial with 20 high-risk people showed that mKRAS-VAX activated immune cells in 18 participants.
omitted byCentercovered byRight side
Sources2 sources cross-checked
Center1
Center-right1
